|5Oct 10, 6:27 PM ET

10X Fund, L.P. 5

5 · GALECTIN THERAPEUTICS INC · Filed Oct 10, 2025

Insider Transaction Report

Form 5
Period: 2024-12-31
Transactions
  • Sale

    Common Stock

    2024-04-22$3.06/sh21,323$65,2485,925,884 total(indirect: By 10X Fund, LP)
  • Sale

    Common Stock

    2024-04-23$3.06/sh3,677$11,2525,922,207 total(indirect: By 10X Fund, LP)
Footnotes (1)
  • [F1]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Documents

1 file
  • 5
    ownership.xmlPrimary

    5